• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Pacira BioSciences Inc. (Amendment)

    2/10/22 8:32:47 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PCRX alert in real time by email
    SC 13G/A 1 tv01612-pacirabiosciencesinc.htm SCHEDULE 13G/A pacirabiosciencesinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 9)*

    Name of issuer:  Pacira BioSciences Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  695127100

    Date of Event Which Requires Filing of this Statement: December 31, 2021

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  695127100

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    84,129

    7.  SOLE DISPOSITIVE POWER

    4,540,561

    8.  SHARED DISPOSITIVE POWER

    125,394

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,665,955

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    10.47%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Pacira BioSciences Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    5401 West Kennedy Boulevard, Suite 890
    Tampa, FL 33609

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    695127100

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2022

    By /s/ Christine M. Buchanan
    Name: Christine M. Buchanan
    Title:  Principal

    Get the next $PCRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PCRX

    DatePrice TargetRatingAnalyst
    12/9/2025$27.00Equal Weight
    Barclays
    11/17/2025Buy
    H.C. Wainwright
    7/25/2025$30.00Hold → Buy
    Truist
    1/30/2025$8.00 → $25.00Sell → Hold
    Truist
    8/13/2024$30.00 → $8.00Buy → Sell
    Truist
    8/12/2024$42.00 → $11.00Overweight → Neutral
    Piper Sandler
    8/12/2024$45.00 → $10.00Overweight → Underweight
    JP Morgan
    8/12/2024Outperform → Mkt Perform
    Raymond James
    More analyst ratings

    $PCRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Cross Shawn exercised 12,941 shares at a strike of $16.45 and sold $325,596 worth of shares (12,941 units at $25.16) as part of a pre-agreed trading plan (SEC Form 4)

    4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

    4/24/26 8:41:26 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Cross Shawn

    4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

    4/22/26 8:03:15 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 4 filed by Kronenfeld Mark A.

    4/A - Pacira BioSciences, Inc. (0001396814) (Issuer)

    3/19/26 5:43:16 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director Nominees

    ISS Concludes "There is a Compelling Reason to Support all Management Nominees" and Notes "the Dissident Has Not Presented a Compelling Case for Change"BRISBANE, Calif., June 1, 2026 /PRNewswire/ -- Pacira BioSciences, Inc. (NASDAQ:PCRX) (the "Company" or "Pacira"), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that leading independent proxy advisory firm Institutional Shareholder Services, Inc. ("ISS") has recommended that Pacira stockholders vote "FOR" each of Pacira's three director nominees – Christopher Christie, Samit Hirawat, MD and Thomas Wiggans – and "AGAINST" all three of DOMA Perpetual Ca

    6/1/26 4:50:00 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote "FOR" All of Pacira's Director Nominees

    BRISBANE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) (the "Company" or "Pacira"), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that leading independent proxy advisory firm Glass Lewis & Co., LLC ("Glass Lewis") has recommended that Pacira stockholders vote "FOR" each of Pacira's three director nominees – Christopher Christie, Samit Hirawat, MD and Thomas Wiggans – and "AGAINST" all three of DOMA Perpetual Capital Management LLC's ("DOMA Perpetual" or "DOMA")1 nominees on the BLUE proxy card ahead of the Company's 2026 Annual Meeting of Stockholders (the "Annual

    5/28/26 4:20:00 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DOMA PERPETUAL CAPITAL MANAGEMENT QUESTIONS WHY SHAREHOLDERS SHOULD VOTE TO CONTINUE WITH A BOARD THAT HAS OVERSEEN A DECADE OF VALUE DESTRUCTION

    PACIRA'S STOCK PRICE IS DOWN FOR EVERY RECENT PERIOD: 10 YEAR, 5 YEAR, 3 YEAR, 2 YEAR, ONE YEAR, AND YEAR-TO-DATEDOMA BELIEVES MANAGEMENT IS MISLEADING STAKEHOLDERS REGARDING ITS PATENT PROTECTION AND MINIMIZING THE POTENTIAL BUSINESS-DESTROYING CONSEQUENCES OF ANOTHER LEGAL LOSS, CONSTITUTING GROSS NEGLIGENCEDOMA CONTENDS THE BOARD IS REFUSING TO EXPLORE A SALE BECAUSE DIRECTORS DO NOT WANT TO LOSE THEIR JOBS, PUTTING THEIR INTERESTS AHEAD OF SHAREHOLDERSMIAMI, May 28, 2026 /PRNewswire/ -- DOMA Perpetual Capital Management ("DOMA Perpetual") is a fundamentals-based, value-oriented asset management firm, which, together with its affiliates (collectively, "DOMA" or "we"), beneficially owns ap

    5/28/26 9:18:00 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Pacira BioSciences with a new price target

    Barclays initiated coverage of Pacira BioSciences with a rating of Equal Weight and set a new price target of $27.00

    12/9/25 8:52:11 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Pacira BioSciences

    H.C. Wainwright initiated coverage of Pacira BioSciences with a rating of Buy

    11/17/25 9:41:22 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pacira BioSciences upgraded by Truist with a new price target

    Truist upgraded Pacira BioSciences from Hold to Buy and set a new price target of $30.00

    7/25/25 8:53:01 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bigal Marcelo bought $20,034 worth of shares (1,512 units at $13.25), increasing direct ownership by 18% to 10,142 units (SEC Form 4)

    4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

    8/19/24 8:25:55 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Brege Laura bought $12,810 worth of shares (1,000 units at $12.81), increasing direct ownership by 6% to 17,552 units (SEC Form 4)

    4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

    8/19/24 8:25:46 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Yang Michael J. bought $25,800 worth of shares (2,000 units at $12.90), increasing direct ownership by 38% to 7,230 units (SEC Form 4)

    4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

    8/14/24 4:35:09 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCRX
    SEC Filings

    View All

    SEC Form DEFA14A filed by Pacira BioSciences Inc.

    DEFA14A - Pacira BioSciences, Inc. (0001396814) (Filer)

    6/1/26 5:14:33 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Pacira BioSciences Inc.

    DEFA14A - Pacira BioSciences, Inc. (0001396814) (Filer)

    5/28/26 4:34:31 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Pacira BioSciences Inc.

    DEFA14A - Pacira BioSciences, Inc. (0001396814) (Filer)

    5/27/26 4:59:31 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCRX
    Financials

    Live finance-specific insights

    View All

    Pacira BioSciences Reports First Quarter 2026 Financial Results

    -- Total revenue of $177 million, reflecting increase of 5 percent over first quarter 2025 driven by growth across commercial portfolio, including EXPAREL volume growth of 7 percent -- -- Completed enrollment in Phase 3 registrational study of ZILRETTA in osteoarthritis pain of the shoulder; study on track for topline readout by end of year -- -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the first quarter of 2026. "Pacira entered 2026 wit

    4/30/26 4:01:00 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pacira to Report First Quarter 2026 Financial Results on Thursday April 30, 2026

    BRISBANE, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its first quarter 2026 financial results after the close of the U.S. markets on Thursday April 30, 2026. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call. In addition, a live audio of th

    4/16/26 8:00:00 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results

    — Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years — — Conference call today at 4:30 p.m. ET — BRISBANE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the fourth quarter and full-year of 2025. "2025 was a year of disciplined execution for Pacira. With the launch of our 5x30 strategy, we reignited momentum across the business and delivered strong, measurable progress. Our products benefitted more than 2.5 million patients

    2/26/26 4:01:00 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCRX
    Leadership Updates

    Live Leadership Updates

    View All

    Pacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company's Strategic Direction and Highly Qualified Nominees

    Clarifies DOMA's Inaccuracies and the Reality of Pacira' Efforts to Strengthen its Market Position Urges Stockholders to Vote "FOR" the Election of Pacira's Highly Qualified Nominees on the BLUE Proxy Card Today BRISBANE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) (the "Company" or "Pacira"), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today issued the following communication with important facts stockholders should know to help protect their Pacira investment. The complete text of the letter mailed to stockholders is as follows: May 27, 2026 Dear Pacira Stockholders, A

    5/27/26 4:20:00 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead

    Conexeu Sciences just 3D-bioprinted a new tissue matrix to one of the most respected regenerative medicine institutes in the world. For investors watching how breast reconstruction — and the wider field of tissue regeneration — evolves, the next 18 months matter. NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary — For more than fifty years, breast reconstruction has mostly meant one thing: replacement. A silicone shell, filled with gel, designed to restore shape and volume, none of them designed to regenerate the breast's own living tissue. That gap has consequences. Roughly two-thirds of the more than 100,000 women in the United States who undergo a mastectomy ea

    5/27/26 9:00:00 AM ET
    $ESTA
    $INMD
    $PCRX
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Biotechnology: Pharmaceutical Preparations

    Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors

    -- Veteran Executive Brings More Than 25 Years of Clinical Development and Industry Expertise -- BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced the appointment of Samit Hirawat, M.D., to its Board of Directors. This appointment increases the size of the company's Board of Directors to 10 members. "Samit is an accomplished and widely respected leader in the biopharmaceutical industry, and we are pleased to welcome him to our Board of Directors," said Laura Brege, independent board chair of Pacira. "We believ

    1/28/26 8:00:00 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Pacira BioSciences Inc. (Amendment)

    SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)

    1/19/24 2:40:54 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Pacira BioSciences Inc. (Amendment)

    SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)

    2/14/23 1:31:32 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Pacira BioSciences Inc. (Amendment)

    SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)

    1/23/23 3:52:35 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care